Participate in a study

About Q-Pharm, a Nucleus Network Company

Q-Pharm specialises in the conduct of early phase (Phases 1 and 2) clinical trials, bioequivalence, biosimilar, bioavailability and vaccine studies. These studies are conducted in our state-of-the-art facility within the QIMR Berghofer precinct at the Royal Brisbane and Women’s Hospital, Brisbane, Australia.

Read more about our approach to Coronavirus (COVID-19) here.

Register your interest to participate in upcoming Coronavirus (COVID-19) vaccine studies.

We provide a comprehensive, high-quality service and conduct clinical trials in accordance with all applicable national and international standards and guidelines.

Q-Pharm’s strength is our highly-qualified clinical trial team, whose leaders have a wealth of clinical development experience. This experience enables us to understand the needs of our diverse clients and deliver, on time, the highest quality clinical services.


How Q-Pharm can help you

  • Safety

    Participant safety is our top priority and our experienced medical staff adhere to the highest industry safety standards. 

  • Quality

    Q-Pharm are fully compliant and regularly meet and exceed audit requirements. 

  • Speed

    With our streamlined design, startup and implementation process, your trial will be completed as quickly as possible.

  • Savings

    Clinical trials with Q-Pharm can cost up to 30% less than USA-based trials.

Experience is everything, and Q-Pharm has the numbers to prove it


Early Phase Studies

We have successfully completed over 400 studies in both healthy and patient populations.


of clinical trials

Q-Pharm has over 15 years’ experience in conducting complex early phase clinical trials

15k + participants

We have had over 15,000 volunteers participate in our clinical trials.

Our Facilities


Mervyn Eadie Clinic

Our 45-bed clinic ideally suited to large-panel healthy volunteer studies and early phase studies.


Wayne Hooper Clinic

Our 17-bed clinic includes 5 private suites, an open plan ward and three treatment/consulting rooms.


Clinical Laboratory

Our clinics are supported by a well-equipped clinic laboratory and experienced staff.



Q-Pharm currently has an on-site pharmacy, facilitating drug preparation on-site.

Client base and testimonials

Q-Pharm services an international client base.  During its years of operation the company has grown from servicing Australian clients only, to one that has a majority of customers that are based overseas.  This international client base has been built upon the premise of delivering quality clinical trial solutions with a thorough understanding of our customer's regulatory needs and requirements.  Q-Pharm works with Pharmaceutical, Biotechnology and Device Industries.  A substantial proportion of our new projects are repeat business or referrals from satisfied clients. While the majority of these clients approach  Q-Pharm directly for clinical trial services, a significant number of projects are also brought to  Q-Pharm via our partner clinical research organisations.

Leslie J. Williams

President and CEO, ImmusanT Inc.

ImmusanT has conducted several Phase 1 studies with Q-Pharm over the past few years. The studies enrolled patients with celiac disease. Our experience with Q-Pharm has been extremely positive and productive at all levels. The Q-Pharm team has shown they are able to fulfill and surpass their enrollment commitments; the staff is highly professional, pro-active and collegial. It has been a real pleasure to work with Q-Pharm.

Neil Finlayson

CEO, Admedus Immunotherapies

Q-Pharm Pty Ltd is the trial site we chose to conduct two of our HSV-2 vaccine trials. Q-Pharm has the best reputation and most experienced investigators and staff to undertake vaccine studies. The first trial was successfully completed in late 2013 in about 6 months, which was mainly due to the efficient and effective team led by Drs. Paul Griffin and Suzanne Elliott. The second study is currently ongoing and we are equally impressed with Q-Pharm and the dedication and hard work of the staff.

Dr. Angus Forster

Chief Development and Operations Officer, Vaxxas

Vaxxas has performed two early stage clinical studies at Q-Pharm using our novel vaccine delivery technology, the Nanopatch.  We selected Q-Pharm based on the experience of their clinical team in running early stage vaccine studies with skin based delivery.  We found the Q-Pharm team to be very engaged and collaborative in their approach supporting us throughout the trial process from protocol development, ethics submission through to study implementation and reporting. Both studies involved a significant amount of skin assessment and photography and we appreciate the hard work of the clinic and data teams in successfully completing these measurements.

Want to know more?

Contact Us